Toboroz
A Phase IIIb Study to Investigate the Effect of Baxdrostat in Chinese Participants With Uncontrolled Hypertension.
NCT07686120· 3. fázis· AstraZeneca· Forrás
Toboroz
Torvutatug Samrotecan Plus Bevacizumab as First-line Maintenance in Non-Homologous Recombination Deficiency (Non-HRD) Positive Advanced Epithelial Ovarian Cancer
NCT07851025· 3. fázis· AstraZeneca· Forrás
Toboroz
A Study of Outcomes in Chinese Patients Treated With Anifrolumab Who Have Active Mod-severe Systemic Lupus Erythematosus
NCT07751848· 3. fázis· AstraZeneca· Forrás
Toboroz
Efficacy and Safety of Ravulizumab in Chinese Adults Participants With Generalized Myasthenia Gravis (gMG)
NCT07596784· 3. fázis· Alexion Pharmaceuticals, Inc.· Forrás
Contact: Alexion Pharmaceuticals, Inc. (Sponsor)
Toboroz
Efficacy, Safety, Pharmacokinetics, Pharmacodynamics, and Immunogenicity Study of Ravulizumab in Chinese Adults With Neuromyelitis Optica Spectrum Disorder (NMOSD)
NCT07557420· 3. fázis· Alexion Pharmaceuticals, Inc.· Forrás
Contact: Alexion Pharmaceuticals, Inc. (Sponsor)
Toboroz
Explore the Diagnostic Value of Bronchodilation Test With Portable Oscillometry in Asthma Diagnosis
NCT07516184· AstraZeneca· Forrás
Toboroz
A Study of MET Concordance and Gene Profiling in 1L NSCLC (Genomet)
NCT07613424· AstraZeneca· Forrás
Toboroz
A Study to Investigate NPS and Symptoms in Chinese Adult Participants With CRSwNP Initiating Treatment With Tezepelumab
NCT07520162· 3. fázis· AstraZeneca· Forrás
Fut, nem toboroz
Implementation of Standardized Early Identification and Diagnosis for Transthyretin Amyloidosis (ATTR) in High-Risk Populations
NCT07338942· AstraZeneca· Forrás
Toboroz
Osimertinib Induction and Maintenance for Chemo-ineligible Stage III Unresectable EGFR+ NSCLC: Single-arm Study
NCT07295821· 2. fázis· AstraZeneca· Forrás
Toboroz
Phase 3b Study in Patients With Severe Asthma Treated With Tezepelumab
NCT07363642· 3. fázis· AstraZeneca· Forrás
Toboroz
AZD5335 vs. Mirvetuximab Soravtansine in FRα-high and AZD5335 vs. Chemotherapy in FRα-low Platinum-resistant Ovarian Cancer
NCT07218809· 3. fázis· AstraZeneca· Forrás
Toboroz
Durvalumab Consolidation After Chemoradiation Therapy for Limited Stage SCLC in China
NCT07161388· AstraZeneca· Forrás
Toboroz
A Multicentre, Single Arm, Non-interventional, Real-world Study to Assess Demographic Characteristics and Patient Reported Outcomes in Patients With Severe Eosinophilic Asthma Treated With Benralizumab in China
NCT06862206· AstraZeneca· Forrás
Fut, nem toboroz
Hyperkalemia Quality Improvement Program (HK-QIP) Study
NCT06884267· AstraZeneca· Forrás
Toboroz
A Global Phase III Study of Rilvegostomig or Pembrolizumab Monotherapy for First-Line Treatment of PD-L1-high Metastatic Non-small Cell Lung Cancer
NCT06868277· 3. fázis· AstraZeneca· Forrás
Toboroz
DESTINY-Endometrial01: A Phase III Study of Trastuzumab Deruxtecan Plus Rilvegostomig or Pembrolizumab as First-Line Treatment of HER2-Expressing (IHC 3+/2+), Mismatch Repair Proficient (pMMR) Endometrial Cancer
NCT06989112· 3. fázis· AstraZeneca· Forrás
Toboroz
A Study to Investigate the Efficacy and Safety of Tezepelumab in Adult Participants With Moderate to Very Severe COPD (D5241C00006)
NCT06883305· 3. fázis· AstraZeneca· Forrás
Toboroz
Phase III Study Investigating Heart Failure and Cardiovascular Death With Baxdrostat in Combination With Dapagliflozin
NCT06677060· 3. fázis· AstraZeneca· Forrás
Fut, nem toboroz
Efficacy, Safety, PK, PD, and ADA of Eculizumab in Chinese Adults With NMOSD
NCT06724809· 3. fázis· Alexion Pharmaceuticals, Inc.· Forrás
Toboroz
A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Squamous Non-small Cell Lung Cancer (NSCLC)
NCT06692738· 3. fázis· AstraZeneca· Forrás
Fut, nem toboroz
A Study in Patients With Myasthenia Gravis in China
NCT06700616· AstraZeneca· Forrás
Toboroz
Non-interventional Study of Patients With Transthyretin (ATTR) Amyloidosis
NCT06465810· AstraZeneca· Forrás
Toboroz
A Study to Investigate Efficacy and Safety of PT027 Compared With PT007 in Symptomatic Chinese Adults With Asthma
NCT06471257· 3. fázis· AstraZeneca· Forrás
Toboroz
DZD8586 in Patients With Relapsed or Refractory CLL/SLL (TAI-SHAN8)
NCT06539182· 2. fázis· Dizal Pharmaceuticals· Forrás
Contact: Tianmo Sun
Toboroz
Phase III, Open-label, Study of First-line Dato-DXd in Combination With Rilvegostomig for Advanced Non-squamous NSCLC With High PD-L1 Expression (TC ≥ 50%) and Without Actionable Genomic Alterations
NCT06357533· 3. fázis· AstraZeneca· Forrás
Fut, nem toboroz
A Study of T-DXd as Monotherapy or in Combination With Anti-cancer Agents in Patients With Selected HER2-expressing Tumors
NCT06271837· 2. fázis· AstraZeneca· Forrás
Toboroz
A Study Evaluating the Efficacy of Budesonide, Glycopyrronium and Formoterol Fumarate Metered Dosed Inhaler on Cardiopulmonary Outcomes in Chronic Obstructive Pulmonary Disease
NCT06283966· 3. fázis· AstraZeneca· Forrás
Toboroz
A Translational Study to Describe Clinical Characteristics, Biomarkers and to Identify Phenotypes and Endotypes Associated With Differential Outcomes in Chinese Population
NCT06419413· AstraZeneca· Forrás
Fut, nem toboroz
Observational Study to Evaluate the Effect and Safety of Selumetinib in Pediatric Patients With NF1-PNs
NCT06175637· AstraZeneca· Forrás
Fut, nem toboroz
EPIC-ATTR: A Study to Evaluate the Effect of Eplontersen on the Transthyretin Reduction and Long-term Safety in Chinese Subjects With Transthyretin Amyloid Cardiomyopathy
NCT06194825· 3. fázis· AstraZeneca· Forrás
Toboroz
A Phase III Study of Dato-DXd With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy in Combination With Pembrolizumab in Patients With PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer (TROPION-Breast05)
NCT06103864· 3. fázis· AstraZeneca· Forrás
Contact: AstraZeneca Breast Cancer Study Locator Service
Fut, nem toboroz
Saruparib (AZD5305) vs Placebo in Men With Metastatic Castration-Sensitive Prostate Cancer Receiving Physician's Choice New Hormonal Agents
NCT06120491· 3. fázis· AstraZeneca· Forrás
Fut, nem toboroz
MEDI5752 in Combination With Carboplatin Plus Pemetrexed in Unresectable Pleural Mesothelioma
NCT06097728· 3. fázis· AstraZeneca· Forrás
Fut, nem toboroz
A Global Study of Volrustomig (MEDI5752) Plus Chemotherapy Versus Pembrolizumab Plus Chemotherapy for Participants With Metastatic Non-small Cell Lung Cancer.
NCT05984277· 3. fázis· AstraZeneca· Forrás
Fut, nem toboroz
Phase III, Open-label, First-line Study of Dato-DXd in Combination With Durvalumab and Carboplatin for Advanced NSCLC Without Actionable Genomic Alterations
NCT05687266· 3. fázis· AstraZeneca· Forrás
Fut, nem toboroz
A Phase III Study of Ceralasertib Plus Durvalumab Versus Docetaxel in Patients With Non Small Cell Lung Cancer (NSCLC) Whose Disease Progressed On or After Prior Anti PD (L)1 Therapy And Platinum Based Chemotherapy
NCT05450692· 3. fázis· AstraZeneca· Forrás
Fut, nem toboroz
Clinical Study to Assess the Efficacy and Safety of Olaparib in Chinese Patients With Metastatic Castration-Resistant Prostate Cancer Who Have Failed Prior Treatment With a New Hormonal Agent and Have BRCA1/2 Mutations
NCT05457257· 4. fázis· AstraZeneca· Forrás
Fut, nem toboroz
A Global Study to Assess the Effects of Osimertinib in Participants With EGFRm Stage IA2-IA3 NSCLC Following Complete Tumour Resection
NCT05120349· 3. fázis· AstraZeneca· Forrás
Fut, nem toboroz
Study of AZD5305 as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Malignancies
NCT04644068· 1/2. fázis· AstraZeneca· Forrás
Fut, nem toboroz
Durvalumab With or Without Olaparib as Maintenance Therapy After First-Line Treatment of Advanced and Recurrent Endometrial Cancer
NCT04269200· 3. fázis· AstraZeneca· Forrás
Fut, nem toboroz
Study of Acalabrutinib Versus Chlorambucil Plus Rituximab in Adult Subjects With Previously Untreated Chronic Lymphocytic Leukemia
NCT04075292· 3. fázis· AstraZeneca· Forrás